The stel­lar an­ti­body shop at Re­gen­eron wins a ‘break­through’ tag for its next big PhI­II drug

Re­gen­eron $REGN has one of the best track records in the busi­ness when it comes to build­ing amaz­ing­ly ef­fec­tive an­ti­bod­ies. It did it with Dupix­ent for eczema and Pralu­ent for cho­les­terol. And now one of its Phase II stars just earned a break­through tag from the FDA, which puts it on the in­side track at the agency as it goes in­to piv­otal stud­ies for slash­ing triglyc­eride.

The drug is evinacum­ab. The tar­get is once again ex­tra­or­di­nar­i­ly high lev­els of LDL cho­les­terol. But the tar­get is dif­fer­ent. This an­ti­body tack­les an­giopoi­etin-like pro­tein 3, or ANGPTL3. ANGPTL3 in­hibits lipopro­tein li­pase and en­dothe­lial li­pase, play­ing a key role in lipopro­tein me­tab­o­lism.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER